News & Updates
Inside Innovation
The latest news and advances from the world's most exciting life science cluster.
AbbVie spends $60M, with $80.5M in biobucks, for Alpine Immune’s lupus asset
Seattle-based Alpine Immune Sciences announced a $60M licensing agreement with AbbVie Inc. for its ALPN-101 midstage lupus and autoimmune asset. Under the pact, AbbVie grabs
BARDA and Immunexpress Inc. expand partnership to evaluate a sepsis host-based laboratory diagnostic to triage COVID-19 patients
Biomedical Advanced Research and Development Authority (BARDA) announced a collaboration with Seattle’s Immunexpress Inc. to determine the risk of sepsis in hospitalized COVID-19 patients. READ
Adaptive Biotechnologies and Microsoft team up to track coronavirus-fighting cells
Adaptive Biotechnologies and Microsoft announced a new project to address COVID-19, called ImmuneCODE. The project tracks how the immune system fights COVID-19 and aims to
Seattle biotech firm scores $85 million for work on Alzheimer’s drug, despite hurdles of coronavirus pandemic
Athira Pharma, a Seattle-based biotechnology company, secured $85 million in a Series B round. The additional financing will support Athira Pharma’s Phase 2/3 Alzheimer’s clinical
‘Start innovating like crazy’: Fast-moving genomics startup turns to R&D to navigate the pandemic
Phase Genomics, a Seattle-based life science company, that maps and analyzes genomes, is focusing its attention inward and renewing its R&D efforts during the pandemic.
Seattle Children’s Hospital and Prevencio: The Hunt to Understand COVID-19’s Connection to Kawasaki Disease
Seattle Children’s Hospital is working with blood-testing startup Prevencio to develop a blood test to detect certain proteins and blood components leading to a firm
Seattle researchers building ‘biobank’ of patients’ blood to unlock the mysteries of the new coronavirus
The Institute for Systems Biology (ISB) and Swedish Health are building a “biobank” to study COVID-19’s impact on the human body. According to Dr. Jim
Nautilus emerges with $76M to become the ‘Illumina of proteomics’
Seattle headquartered, Nautilus Biotechnology announced a $76 million series B round to fund its work analyzing and quantifying the human proteome. Nautilus Biotechnology is looking
Seattle biotech CEO keeps a watchful eye on the market for potential IPO
Kineta Inc. CEO, Shawn Iadonato recently spoke to PSBJ about laying the groundwork for an IPO. Iadonato told PSBJ’s Megan Campbell, “We’re really watching the capital markets closely.
Seattle Genetics, Astellas’ bladder cancer med Padcev blows early expectations out of the water
Seattle-based Seattle Genetics and Astellas’ new bladder cancer treatment, Pandcev exceeded sales expectations in Q1. In a note to clients, J.P. Morgan analyst, Cory Kasimov
General Motors and Ventec to deliver first batch of ventilators ahead of schedule
General Motors and Bothell-based Ventec Life Systems are participating in a joint effort to build ventilators and add to the nation’s stockpile used to care
Adaptive Biotech’s deal with Amgen influenced by belief that COVID-19 may return seasonally, like flu
Amgen plans to use Adaptive Biotech’s proprietary technology platform to develop therapies to treat the coronavirus, especially for those working on the frontlines treating patients.